The Coming of Age of Drug-Susceptibility Testing for Tuberculosis.

Helen Cox, Valerie Mizrahi

Abstract readEditorialComment

In one paragraph

Article in The New England journal of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine.Nature communications · 2021
Article
Occult drug resistance in tuberculosis: Emerging issues, upcoming challenges & possible solutions.The Indian journal of medical research · 2020
Article
Intervening along the spectrum of tuberculosis: meeting report from the World TB Day nanosymposium in the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town.Gates open research · 2019
Article

4 · The record

Corrections and comments

Comment on
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.2018

5 · Who and what money

Authors and funding

2 authors.

Helen CoxFrom the Institute of Infectious Disease and Molecular Medicine and the Department of Pathology, Wellcome Centre for Infectious Diseases Research in Africa (H.C., V.M.), and the South African Medical Research Council/National Health Laboratory Service/University of Cape Town Molecular Mycobacteriology Research Unit, University of Cape Town (V.M.), Cape Town, South Africa.

Valerie MizrahiFrom the Institute of Infectious Disease and Molecular Medicine and the Department of Pathology, Wellcome Centre for Infectious Diseases Research in Africa (H.C., V.M.), and the South African Medical Research Council/National Health Laboratory Service/University of Cape Town Molecular Mycobacteriology Research Unit, University of Cape Town (V.M.), Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antitubercular AgentsTuberculosisHumansMicrobial Sensitivity TestsMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID30256713

DOI10.1056/NEJMe1811861

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.